title: Proteomic analysis of the effects of baicalein on colorectal cancer cells.
abstract: Baicalein is the flavonoids with multiple pharmacological activities. The aim of our study was to investigate the effects of baicalein on colorectal cancer (CRC) and to recognize the targets of baicalein treatment. To better understand baicalein's target, proteomic approaches were used to purify and identify the protein substrates using 2D difference gel electrophoresis (2D SDS-PAGE) to elucidate proteins differential display. Results from this study investigate that baicalein treatment of CRC cells results in reduced cell proliferation. As a result, differential protein displays between baicalein-treated and untreated CRC were determined and validated. There were 11 differentially expressed proteins between baicalein-treated and untreated CRC. Furthermore, we demonstrate that baicalein inhibits cancer cell proliferation and reduced reactive oxygen species (ROS) by up-regulating the levels of peroxiredoxin-6 (PRDX6). Knockdown of PRDX6 in baicalein-treated CRC cells by specific small interfering RNA resulted in ROS production and proliferation, opposite of the baicalein treatment scenario as indicated by cell cycle distribution. These results illustrate that baicalein up-regulates the expression of PRDX6, which attenuates the generation of ROS and inhibits the growth of CRC cells, whereas baicalein treatment have no effect on normal epithelial cells.
authors.affiliation: Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan.
authors.forename: Wen-Shih
authors.initials: WS
authors.lastname: Huang
authors.forename: Yi-Hung
authors.initials: YH
authors.lastname: Kuo
authors.forename: Chih-Chien
authors.initials: CC
authors.lastname: Chin
authors.forename: Jeng-Yi
authors.initials: JY
authors.lastname: Wang
authors.forename: Hong-Ren
authors.initials: HR
authors.lastname: Yu
authors.forename: Jiunn-Ming
authors.initials: JM
authors.lastname: Sheen
authors.forename: Shui-Yi
authors.initials: SY
authors.lastname: Tung
authors.forename: Chien-Heng
authors.initials: CH
authors.lastname: Shen
authors.forename: Te-Chuan
authors.initials: TC
authors.lastname: Chen
authors.forename: Mei-Lan
authors.initials: ML
authors.lastname: Sung
authors.forename: Hwey-Fang
authors.initials: HF
authors.lastname: Liang
authors.forename: Hsing-Chun
authors.initials: HC
authors.lastname: Kuo
mesh_terms: D000975:Antioxidants / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D044950:Flavanones / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D055785:Gene Knockdown Techniques; D006801:Humans; D054465:Peroxiredoxin VI / Q000235:genetics / Q000378:metabolism; D020543:Proteome / Q000032:analysis* / Q000235:genetics; D040901:Proteomics; D017382:Reactive Oxygen Species / Q000378:metabolism; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D000975:Antioxidants; D044950:Flavanones; D020543:Proteome; D017382:Reactive Oxygen Species; C006680:baicalein; D054465:Peroxiredoxin VI